ProstACT Global Phase 3 Update: First Patient Dosed, Part 1 Preliminary Data Plans ConfirmedTelix recently announced that its lead prostate cancer candidate TLX591 (lutetium-177 ro...
When undergoing targeted cancer therapy, diet often becomes a concern for many patients. The truth is, there’s no need for overly strict restrictions, but maintaining a light, bal...